drugset
drugset / Trial / NCT01941511

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

NCT01941511 ↗

Phase 1 Completed 48 enrolled GlycoMimetics Incorporated
CrossoverTriple-blindOther

Summary

This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.

Timeline

Start
2013-08
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivipansel Small molecule 4 g Intravenous
Subject Rivipansel Small molecule 4.8 g Intravenous

Indications

No indication recorded.